According to a release posted on the company website, the total revenue increased by 9 per cent to Rs 793 crore (Rs 7.93 billion) from Rs 728 crore (Rs 7.28 billion) in FY05.
The board has announced a dividend of 50 per cent i.e Rs 2.50 per share, the release added.
Kiran Mazumdar-Shaw, chairman & managing director of Biocon, said, "I am pleased that we have sustained a healthy 30 per cent operating margin for the financial year 2005-06 despite a fiercely competitive environment. This enables us to continue to invest in our discovery led research programs."
"The recent acquisition of the NOBEX portfolio has significantly enhanced our IP assets - both in terms of patents as well as proprietary technologies - which will play a key role in our innovation strategy for the future. The year ahead is also expected to see us entering the oncology market with our novel antibody product, BIOMAB-EGFR, for the treatment of head and neck cancers. We believe our balanced portfolio of products and services will deliver superior shareholder value over the medium-to-long term," she added.
Dr. Arun Chandavarkar has been appointed chief operating officer of Biocon with eefect from 1 April, 2006. Rakesh Bamzai has been appointed president (marketing).